Evaluation of Olaratumab (IMC-3G3) an Anti-PDGFR Antibody, with or without Concomitant Chemotherapy Against Pediatric Cancer Xenografts with High Level PDGFR Expression
Source: Eli Lilly & Company
Period: 05/15/2017 – 5/14/2019
Title: Evaluation of Olaratumab (IMC-3G3) an Anti-PDGFR Antibody, with or without Concomitant Chemotherapy Against Pediatric Cancer Xenografts with High Level PDGFR Expression
Project Goal: Evaluate olaratumab (anti-PDGFRalpha antibody) with or without standard care of chemotherapy (1 agent) or LSC3214996 against KT-12 and KT-14 rhabdoid xenograft models.
Role: Co-Investigator